{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000051","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.607581+00:00","generated_at":"2026-05-16T15:52:42.491825+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026","bullets":["Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.","AKB-097 is a tissue-targeted C3d-Factor H fusion protein complement inhibitor; Phase 2 basket trial in multiple rare kidney diseases planned to start treating subjects in 2026.","Praliciguat (sGC stimulator) Phase 2 trial initiated in FSGS; additional rare podocytopathy indications planned.","Existing cash resources plus cash from operations expected to fund current operating plan for at least 2 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000051","json":"https://secwatch.observer/filing/0001517022-25-000051.json","markdown":"https://secwatch.observer/filing/0001517022-25-000051.md","text":"https://secwatch.observer/filing/0001517022-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000051/0001517022-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000051/akba-20251128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:52:42.491825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}